Fundacja Badań i Rozwoju Nauki
Develops 3D bioprinted bionic pancreas for diabetes treatment using CELLINK Bio X bioprinters and proprietary bioinks from animal pancreatic islets.
- CEO / Founder
- Filip Piotr Fertner
- Team Size
- 1-10
- Stage
- Active
- Key Investors
- Narodowe Centrum Badań i Rozwoju (NCBR), Narodowe Centrum Nauki (NCN), Unia Europejska (Europejski Fundusz Rozwoju Regionalnego)
Technology & Products
Key Products
3D bioprinted bionic pancreas prototype
Technological Advantage
Proprietary bioink development from animal pancreatic islets producing insulin and glucagon; integration with custom-designed active bioreactor for cell culture control.
Differentiation
Value Proposition
Aims to create functional bionic pancreas for transplantation, addressing organ shortage and chronic immunosuppression risks in diabetes treatment.
How They Differentiate
Focus on 3D bioprinting of functional bionic pancreas for diabetes treatment, unlike general bioprinting companies; part of BIONIC Consortium with strong academic partnerships.
Market & Competition
Target Customers
Medical research institutions, hospitals, diabetes treatment centers
Industry Verticals
Medical; Biotechnology
Competitors
CELLINK; Organovo; Aspect Biosystems
Growth & Milestones
Growth Metrics
Implemented many impressive projects during 9 years of activity; financed and conducted pioneer research on endoscopic procedures
Major Milestones
First 3D printed prototype of vascularized bionic pancreas achieved in March 2019; Purchase of CELLINK Bio X bioprinter in August 2018; Goal to bioprint functional bionic pancreas by 2022
Notable Customers
Department and General and Transplant Surgery of the Jesus Child Hospital; Warsaw University of Life Sciences